Waltham, United States
Dyne Therapeutics, founded in 2018 and headquartered in the United States, is a dynamic player in the Biotechnology, Health Care, and Pharmaceutical industries. With a slogan of "Advancing life-transforming therapies for serious muscle diseases," the company is committed to addressing significant unmet needs in neuromuscular diseases.
Focused on genetically driven disorders, Dyne Therapeutics develops therapeutics targeting both muscle and the central nervous system, tackling the root causes of diseases like Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and others in preclinical stages such as facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.
The company's last financial milestone was a Post-IPO Equity investment on 21 May 2024. While specific investor details weren't disclosed, this investment provides a robust platform for Dyne Therapeutics to continue its mission of delivering functional improvement to communities worldwide.
Entrada Therapeutics